Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 14/20 | 0.55 |
| ▸ | MC4R | P32245 | 1/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6485221 | 0.93 | MC4R (0.58) | AVPR1BMC4RMCHR1 | |
| SCHEMBL6474142 | 0.93 | MC4R (0.52) | AVPR1BMC4RMCHR1 | |
| SCHEMBL6474588 | 0.92 | MC4R (0.59) | AVPR1BMC4RMCHR1 | |
| SCHEMBL6480290 | 0.91 | MC4R (0.51) | AVPR1BMC4RMCHR1 | |
| SCHEMBL6485926 | 0.89 | MAOB (0.49) | AVPR1BMC4RMCHR1 | |
| SCHEMBL6475167 | 0.89 | DRD2 (0.53) | AVPR1BMC4RMCHR1 | |
| SCHEMBL6484254 | 0.86 | PDE3B (0.50) | MC4RALDH1A1TSHRSMN1; SMN2NPSR1 | |
| SCHEMBL6483313 | 0.86 | PDE3B (0.50) | MC4RALDH1A1TSHRSMN1; SMN2NPSR1 | |
| SCHEMBL6475480 | 0.85 | MAOB (0.51) | MC4RMCHR1 | |
| SCHEMBL6482649 | 0.85 | HRH2 (0.48) | MC4RMCHR1ALDH1A1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855714-B2 | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-02-15 | — | — | US | claimed |
| EP-1404321-A1 | 1-ALKYL-2-ARYL-BENZIMIDAZOLE DERIVATIVES, THEIR USE FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | Schering Aktiengesellschaft (DE) | 2004-04-07 | — | — | EP | claimed |
| US-20030055057-A1 | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutial agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AG (DE) | 2003-03-20 | — | — | US | claimed |
| WO-2003004023-A1 | 1-ALKYL-2-ARYL-BENZIMIDAZOLE DERIVATIVES, THEIR USE FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-01-16 | — | — | WO | claimed |
| US-6855714-B2 | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-02-15 | — | — | US | disclosed |
| EP-1404321-A1 | 1-ALKYL-2-ARYL-BENZIMIDAZOLE DERIVATIVES, THEIR USE FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | Schering Aktiengesellschaft (DE) | 2004-04-07 | — | — | EP | disclosed |
| US-20030055057-A1 | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutial agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AG (DE) | 2003-03-20 | — | — | US | disclosed |
| WO-2003004023-A1 | 1-ALKYL-2-ARYL-BENZIMIDAZOLE DERIVATIVES, THEIR USE FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055057-A1 | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutial agents as well as pharmaceutical preparations that contain these derivatives | ARG2, MSR1, ARG1 | AVPR1B 2285/4885MC4R 1554/4885MCHR1 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.